These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Recommendations concerning the introduction of generic formulations of cyclosporine. Kahan BD Transplant Proc; 1999 May; 31(3):1634; discussion 1675-84. PubMed ID: 10331030 [No Abstract] [Full Text] [Related]
3. When do differences in dissolution profiles predict clinical problems? Ngo SN J Clin Pharm Ther; 2007 Apr; 32(2):111-2. PubMed ID: 17381660 [No Abstract] [Full Text] [Related]
4. [Preventable problems in thyroid hormone substitution therapy. The risks of brand change are unpredictable]. MMW Fortschr Med; 2010 Jun; 152(22):46-7. PubMed ID: 20590034 [No Abstract] [Full Text] [Related]
5. Comparative bioavailability of the microemulsion formulation of cyclosporine (Neoral) with a generic dispersion formulation (Cicloral) in young healthy male volunteers. Kees F; Bucher M; Schweda F; Gschaidmeier H; Burhenne J; Mikus G; Faerber L Ther Drug Monit; 2006 Jun; 28(3):312-20. PubMed ID: 16778713 [TBL] [Abstract][Full Text] [Related]
11. Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients. Hibberd AD; Trevillian PR; Roger SD; Wlodarczyk JH; Stein AM; Bohringer EG; Milson-Hawke SM Transplantation; 2006 Mar; 81(5):711-7. PubMed ID: 16534473 [TBL] [Abstract][Full Text] [Related]
12. FDA mulls changes to bioequivalence standards. Traynor K Am J Health Syst Pharm; 2010 Jun; 67(11):864. PubMed ID: 20484205 [No Abstract] [Full Text] [Related]
13. A pharmacokinetic comparison of generic tablets containing bisoprolol with the innovator formulation in healthy volunteers. Jovanović D; Cusić S; Rancić D; Srnić D; Perković-Vukcević N J Clin Pharmacol; 2006 Oct; 46(10):1217-22. PubMed ID: 16988212 [No Abstract] [Full Text] [Related]
14. Generic warfarin: implications for patient care. Wittkowsky AK Pharmacotherapy; 1997; 17(4):640-3. PubMed ID: 9250543 [No Abstract] [Full Text] [Related]
15. Generic warfarin: implications for patient care--another view. Meyer M; Chan K; Bolton S Pharmacotherapy; 1998; 18(4):884-6; discussion 887-9. PubMed ID: 9692670 [No Abstract] [Full Text] [Related]
16. Comments on the note for guidance on bioavailability and bioequivalence in the European Union. Calvo G Methods Find Exp Clin Pharmacol; 1998; 20 Suppl A():11. PubMed ID: 9800721 [No Abstract] [Full Text] [Related]
18. The cost of gullibility. Roach ES Arch Neurol; 2009 Nov; 66(11):1418-20. PubMed ID: 19901178 [No Abstract] [Full Text] [Related]
19. Problems with the automatic switching of generic cyclosporine oral solution for the innovator product. Haug M; Wimberley SL Am J Health Syst Pharm; 2000 Jul; 57(14):1349-53. PubMed ID: 10918926 [No Abstract] [Full Text] [Related]
20. Bioequivalence and interchangeability of narrow therapeutic range drugs. Canadian Society for Pharmaceutical Sciences discussion. Palylyk-Colwell E; Jamali F; Dryden W; Friesen E; Koven S; Mohamed I; Osmond B; Alessi-Severini S; Sheldon L; Sheldon R; Tam Y; Tsuyuki R; Zhanel G J Pharm Pharm Sci; 1998; 1(1):2-7. PubMed ID: 10942966 [No Abstract] [Full Text] [Related] [Next] [New Search]